Protease inhibitor therapy and fetal growth potential in HIV-positive women

Sara Iqbal, Jan Kriebs, Christopher Harman, Sadettin Gungor, Lindsay Alger, Ozhan Turan, Jerome Kopelman, Andrew Malinow, Ahmet Baschat

Research output: Contribution to journalArticle

Abstract

Our objective was to test if protease inhibitors (PIs) increase the incidence of fetal growth restriction (FGR). Human immunodeficiency (HIV)-seropositive women were studied. At birth the neonatal weight percentile was assigned by predicted growth potential (GP), accounting for race, parity, weight, height, gestational age, birthweight, and gender (Gardosi, 1992). FGR was defined as GP <10% percentile. Maternal age, CD4 count, viral load, weight gain, prenatal care, tobacco, alcohol, substance abuse, and PI use were related to FGR using chi-square and multiple regression analysis. Ninety-three of 191 women received PI. In these, FGR occurred in 27 (29%) compared with 15 (15.3%) in the non-PI group (p = 0.02). Maternal CD4 count (p <0.0001) was the primary determinant, and smoking (p = 0.037) was an independent cofactor for FGR (Nagelkerke r2 = 0.24). Twenty-six of 82 (31.7%) smokers had FGR, versus 16 of 109 (14.7%) of nonsmokers (odds ratio, 2.69; 95% confidence interval, 1.33 to 5.46; p = 0.005). After exclusion of the CD4 count, PI became a cofactor for FGR (p = 0.021 and Nagelkerke r2 = 0.104). We concluded that maternal HIV status and smoking determine the risk for FGR. Although PIs increase the risk for FGR, this effect appears to depend on maternal disease severity.

Original languageEnglish (US)
Pages (from-to)335-339
Number of pages5
JournalAmerican Journal of Perinatology
Volume25
Issue number6
DOIs
StatePublished - 2008
Externally publishedYes

Fingerprint

Fetal Development
Protease Inhibitors
HIV
CD4 Lymphocyte Count
Therapeutics
Mothers
Smoking
Prenatal Care
Maternal Age
Growth
Parity
Viral Load
Birth Weight
Alcoholism
Gestational Age
Weight Gain
Substance-Related Disorders
Tobacco
Odds Ratio
Regression Analysis

Keywords

  • Antiretroviral therapy
  • Fetal growth restriction
  • HIV
  • Pregnancy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Protease inhibitor therapy and fetal growth potential in HIV-positive women. / Iqbal, Sara; Kriebs, Jan; Harman, Christopher; Gungor, Sadettin; Alger, Lindsay; Turan, Ozhan; Kopelman, Jerome; Malinow, Andrew; Baschat, Ahmet.

In: American Journal of Perinatology, Vol. 25, No. 6, 2008, p. 335-339.

Research output: Contribution to journalArticle

Iqbal, S, Kriebs, J, Harman, C, Gungor, S, Alger, L, Turan, O, Kopelman, J, Malinow, A & Baschat, A 2008, 'Protease inhibitor therapy and fetal growth potential in HIV-positive women', American Journal of Perinatology, vol. 25, no. 6, pp. 335-339. https://doi.org/10.1055/s-2008-1078757
Iqbal, Sara ; Kriebs, Jan ; Harman, Christopher ; Gungor, Sadettin ; Alger, Lindsay ; Turan, Ozhan ; Kopelman, Jerome ; Malinow, Andrew ; Baschat, Ahmet. / Protease inhibitor therapy and fetal growth potential in HIV-positive women. In: American Journal of Perinatology. 2008 ; Vol. 25, No. 6. pp. 335-339.
@article{82c6259485374ed99abb16f5f54a99ab,
title = "Protease inhibitor therapy and fetal growth potential in HIV-positive women",
abstract = "Our objective was to test if protease inhibitors (PIs) increase the incidence of fetal growth restriction (FGR). Human immunodeficiency (HIV)-seropositive women were studied. At birth the neonatal weight percentile was assigned by predicted growth potential (GP), accounting for race, parity, weight, height, gestational age, birthweight, and gender (Gardosi, 1992). FGR was defined as GP <10{\%} percentile. Maternal age, CD4 count, viral load, weight gain, prenatal care, tobacco, alcohol, substance abuse, and PI use were related to FGR using chi-square and multiple regression analysis. Ninety-three of 191 women received PI. In these, FGR occurred in 27 (29{\%}) compared with 15 (15.3{\%}) in the non-PI group (p = 0.02). Maternal CD4 count (p <0.0001) was the primary determinant, and smoking (p = 0.037) was an independent cofactor for FGR (Nagelkerke r2 = 0.24). Twenty-six of 82 (31.7{\%}) smokers had FGR, versus 16 of 109 (14.7{\%}) of nonsmokers (odds ratio, 2.69; 95{\%} confidence interval, 1.33 to 5.46; p = 0.005). After exclusion of the CD4 count, PI became a cofactor for FGR (p = 0.021 and Nagelkerke r2 = 0.104). We concluded that maternal HIV status and smoking determine the risk for FGR. Although PIs increase the risk for FGR, this effect appears to depend on maternal disease severity.",
keywords = "Antiretroviral therapy, Fetal growth restriction, HIV, Pregnancy",
author = "Sara Iqbal and Jan Kriebs and Christopher Harman and Sadettin Gungor and Lindsay Alger and Ozhan Turan and Jerome Kopelman and Andrew Malinow and Ahmet Baschat",
year = "2008",
doi = "10.1055/s-2008-1078757",
language = "English (US)",
volume = "25",
pages = "335--339",
journal = "American Journal of Perinatology",
issn = "0735-1631",
publisher = "Thieme Medical Publishers",
number = "6",

}

TY - JOUR

T1 - Protease inhibitor therapy and fetal growth potential in HIV-positive women

AU - Iqbal, Sara

AU - Kriebs, Jan

AU - Harman, Christopher

AU - Gungor, Sadettin

AU - Alger, Lindsay

AU - Turan, Ozhan

AU - Kopelman, Jerome

AU - Malinow, Andrew

AU - Baschat, Ahmet

PY - 2008

Y1 - 2008

N2 - Our objective was to test if protease inhibitors (PIs) increase the incidence of fetal growth restriction (FGR). Human immunodeficiency (HIV)-seropositive women were studied. At birth the neonatal weight percentile was assigned by predicted growth potential (GP), accounting for race, parity, weight, height, gestational age, birthweight, and gender (Gardosi, 1992). FGR was defined as GP <10% percentile. Maternal age, CD4 count, viral load, weight gain, prenatal care, tobacco, alcohol, substance abuse, and PI use were related to FGR using chi-square and multiple regression analysis. Ninety-three of 191 women received PI. In these, FGR occurred in 27 (29%) compared with 15 (15.3%) in the non-PI group (p = 0.02). Maternal CD4 count (p <0.0001) was the primary determinant, and smoking (p = 0.037) was an independent cofactor for FGR (Nagelkerke r2 = 0.24). Twenty-six of 82 (31.7%) smokers had FGR, versus 16 of 109 (14.7%) of nonsmokers (odds ratio, 2.69; 95% confidence interval, 1.33 to 5.46; p = 0.005). After exclusion of the CD4 count, PI became a cofactor for FGR (p = 0.021 and Nagelkerke r2 = 0.104). We concluded that maternal HIV status and smoking determine the risk for FGR. Although PIs increase the risk for FGR, this effect appears to depend on maternal disease severity.

AB - Our objective was to test if protease inhibitors (PIs) increase the incidence of fetal growth restriction (FGR). Human immunodeficiency (HIV)-seropositive women were studied. At birth the neonatal weight percentile was assigned by predicted growth potential (GP), accounting for race, parity, weight, height, gestational age, birthweight, and gender (Gardosi, 1992). FGR was defined as GP <10% percentile. Maternal age, CD4 count, viral load, weight gain, prenatal care, tobacco, alcohol, substance abuse, and PI use were related to FGR using chi-square and multiple regression analysis. Ninety-three of 191 women received PI. In these, FGR occurred in 27 (29%) compared with 15 (15.3%) in the non-PI group (p = 0.02). Maternal CD4 count (p <0.0001) was the primary determinant, and smoking (p = 0.037) was an independent cofactor for FGR (Nagelkerke r2 = 0.24). Twenty-six of 82 (31.7%) smokers had FGR, versus 16 of 109 (14.7%) of nonsmokers (odds ratio, 2.69; 95% confidence interval, 1.33 to 5.46; p = 0.005). After exclusion of the CD4 count, PI became a cofactor for FGR (p = 0.021 and Nagelkerke r2 = 0.104). We concluded that maternal HIV status and smoking determine the risk for FGR. Although PIs increase the risk for FGR, this effect appears to depend on maternal disease severity.

KW - Antiretroviral therapy

KW - Fetal growth restriction

KW - HIV

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=52249117650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52249117650&partnerID=8YFLogxK

U2 - 10.1055/s-2008-1078757

DO - 10.1055/s-2008-1078757

M3 - Article

C2 - 18509788

AN - SCOPUS:52249117650

VL - 25

SP - 335

EP - 339

JO - American Journal of Perinatology

JF - American Journal of Perinatology

SN - 0735-1631

IS - 6

ER -